Clinical Trials Directory

Trials / Completed

CompletedNCT02385097

Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
211 (actual)
Sponsor
Sintetica SA · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.

Detailed description

This Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min (see definitions below), calculated from the time of readiness for surgery (complete sensory block). Successful block: anaesthesia adequate for the surgery (complete sensory block), without any supplementation in the first 45 min (even if surgery lasts for \> 45 min), calculated from the time of readiness for surgery (complete sensory block). Supplementation: i.v. premedication or general anaesthesia or pre- or intra-operative systemic analgesia or additional local anaesthetic infiltration

Conditions

Interventions

TypeNameDescription
DRUGChloroprocaine HCl 2%Single Administration (20mL) by Axillary Nerve Route
DRUGRopivacaine 0.75%Single Administration (20mL) by Axillary Nerve Route

Timeline

Start date
2015-04-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2015-03-11
Last updated
2021-07-15
Results posted
2021-07-15

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02385097. Inclusion in this directory is not an endorsement.